Search

Your search keyword '"Camus, Vincent"' showing total 911 results
Start Over Author "Camus, Vincent"
911 results on '"Camus, Vincent"'

206. Invasive infections due to Saprochaete and Geotrichum species: Report of 23 cases from the FungiScope Registry

Author

Durán Graeff, Luisa, Seidel, Danila, Vehreschild, Maria J. G. T., Hamprecht, Axel, Kindo, Anupma, Racil, Zdenek, Demeter, Judit, De Hoog, Sybren, Aurbach, Ute, Ziegler, Maren, Wisplinghoff, Hilmar, Cornely, Oliver A., Alakel, Nael, Arsenijevic, Valentina Arsic, Balkan, Ilker I., Camus, Vincent, Cetkovsky, Petr, Demiraslan, Hayati, Gruhn, Bernd, Heinz, Werner, Hofmann, Vanessa, Horakova, Julia, Kouba, Michal, Miglietta, Fabio, Pagano, Livio, Pasqualotto, Alessandro, Plantefève, Gaëtan, Rolencová, Monika, Tanuskova, Dominika, Pagano, Livio (ORCID:0000-0001-8287-928X), Durán Graeff, Luisa, Seidel, Danila, Vehreschild, Maria J. G. T., Hamprecht, Axel, Kindo, Anupma, Racil, Zdenek, Demeter, Judit, De Hoog, Sybren, Aurbach, Ute, Ziegler, Maren, Wisplinghoff, Hilmar, Cornely, Oliver A., Alakel, Nael, Arsenijevic, Valentina Arsic, Balkan, Ilker I., Camus, Vincent, Cetkovsky, Petr, Demiraslan, Hayati, Gruhn, Bernd, Heinz, Werner, Hofmann, Vanessa, Horakova, Julia, Kouba, Michal, Miglietta, Fabio, Pagano, Livio, Pasqualotto, Alessandro, Plantefève, Gaëtan, Rolencová, Monika, Tanuskova, Dominika, and Pagano, Livio (ORCID:0000-0001-8287-928X)

Abstract

Saprochaete and Geotrichum spp. are rare emerging fungi causing invasive fungal diseases in immunosuppressed patients and scarce evidence is available for treatment decisions. Among 505 cases of rare IFD from the FungiScopeTM registry, we identified 23 cases of invasive infections caused by these fungi reported from 10 countries over a 12-year period. All cases were adults and previous chemotherapy with associated neutropenia was the most common co-morbidity. Fungaemia was confirmed in 14 (61%) cases and deep organ involvement included lungs, liver, spleen, central nervous system and kidneys. Fungi were S. capitata (n=14), S. clavata (n=5), G. candidum (n=2) and Geotrichum spp. (n=2). Susceptibility was tested in 16 (70%) isolates. All S. capitata and S. clavata isolates with the exception of one S. capitata (MIC 4 mg/L) isolate had MICs>32 mg/L for caspofungin. For micafungin and anidulafungin, MICs varied between 0.25 and >32 mg/L. One case was diagnosed postmortem, 22 patients received targeted treatment, with voriconazole as the most frequent first line drug. Overall mortality was 65% (n=15). Initial echinocandin treatment was associated with worse outcome at day 30 when compared to treatment with other antifungals (amphotericin B ± flucytosine, voriconazole, fluconazole and itraconazole) (P=.036). Echinocandins are not an option for these infections.

Published
2017

207. Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma

Author

Jardin, Fabrice, Pujals, Anais, Pelletier, Laura, Bohers, Elodie, Camus, Vincent, Mareschal, Sylvain, Dubois, Sydney, Sola, Brigitte, Ochmann, Marlène, Lemonnier, François, Viailly, Pierre-Julien, Bertrand, Philippe, Maingonnat, Catherine, Traverse-Glehen, Alexandra, Gaulard, Philippe, Damotte, Diane, Delarue, Richard, Haioun, Corinne, Argueta, Christian, Landesman, Yosef, Salles, Gilles, Jais, Jean-Philippe, Figeac, Martin, Copie-Bergman, Christiane, Molina, Thierry Jo, Picquenot, Jean Michel, Cornic, Marie, Fest, Thierry, Milpied, Noel, Lemasle, Emilie, Stamatoullas, Aspasia, Moeller, Peter, Dyer, Martin J S, Sundström, Christer, Bastard, Christian, Tilly, Hervé, Leroy, Karen, Groupe d'étude des proliférations lymphoïdes ( GPL ), Université de Rouen Normandie ( UNIROUEN ), Normandie Université ( NU ) -Normandie Université ( NU ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Service d'hématologie clinique, Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), Microenvironnement cellulaire et pathologie ( MILPAT ), Université de Caen Normandie ( UNICAEN ), Normandie Université ( NU ) -Normandie Université ( NU ), Microenvironnement et cancer ( MiCa ), Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Centre de Recherche des Cordeliers ( CRC (UMR_S 872) ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), CHU Necker - Enfants Malades [AP-HP], Service d'hématologie [Hôpital Edouard Herriot - HCL], Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon ( HCL ) -Hospices Civils de Lyon ( HCL ), Institut pour la recherche sur le cancer de Lille [Lille] ( IRCL ), Institut Mondor de Recherche Biomédicale ( IMRB ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), Université Paris Descartes - Paris 5 ( UPD5 ), Centre hospitalier universitaire de Nantes ( CHU Nantes ), Institute of Human Genetics, University of Ulm, Albert-Einstein-Allee 11, Ulm, Germany, University of Leicester, Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden, Service hématologie Poitiers, Centre hospitalier universitaire de Poitiers ( CHU Poitiers ), The authors thank Dr. Lin Chook for her critical review and for providing the molecular data on the conformation of XPO1/CRM1 protein residues., Groupe d'étude des proliférations lymphoïdes (GPL), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Microenvironnement cellulaire et pathologie (MILPAT), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU), Microenvironnement et cancer (MiCa), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Centre de Recherche des Cordeliers (CRC (UMR_S 872)), Université Pierre et Marie Curie - Paris 6 (UPMC)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Institut pour la recherche sur le cancer de Lille [Lille] (IRCL), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Université Paris Descartes - Paris 5 (UPD5), Centre hospitalier universitaire de Nantes (CHU Nantes), Universität Ulm - Ulm University [Ulm, Allemagne], Uppsala University, Centre hospitalier universitaire de Poitiers (CHU Poitiers), Chard-Hutchinson, Xavier, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Université Paris Descartes - Paris 5 (UPD5)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), and Institute of Human Genetics, University of Ulm

Subjects
[SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/Hematology, Adult, Male, Lymphoma, B-Cell, Adolescent, Active Transport, Cell Nucleus, Receptors, Cytoplasmic and Nuclear, [SDV.CAN]Life Sciences [q-bio]/Cancer, Karyopherins, Mediastinal Neoplasms, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, Young Adult, [SDV.CAN] Life Sciences [q-bio]/Cancer, Cell Line, Tumor, [ SDV.MHEP.HEM ] Life Sciences [q-bio]/Human health and pathology/Hematology, Humans, Aged, Clinical Laboratory Medicine, Gene Expression Profiling, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, Sequence Analysis, DNA, Middle Aged, Triazoles, Hodgkin Disease, Klinisk laboratoriemedicin, Hydrazines, Acrylates, Mutation, Female, Biomarkers
Abstract

Primary mediastinal B-cell lymphoma (PMBL) is an entity of B-cell lymphoma distinct from the other molecular subtypes of diffuse large B-cell lymphoma (DLBCL). We investigated the prevalence, specificity, and clinical relevance of mutations of XPO1, which encodes a member of the karyopherin-β nuclear transporters, in a large cohort of PMBL. PMBL cases defined histologically or by gene expression profiling (GEP) were sequenced and the XPO1 mutational status was correlated to genetic and clinical characteristics. The XPO1 mutational status was also assessed in DLBCL, Hodgkin lymphoma (HL) and mediastinal gray-zone lymphoma (MGZL).The biological impact of the mutation on Selective Inhibitor of Nuclear Export (SINE) compounds (KPT-185/330) sensitivity was investigated in vitro. XPO1 mutations were present in 28/117 (24%) PMBL cases and in 5/19 (26%) HL cases but absent/rare in MGZL (0/20) or DLBCL (3/197). A higher prevalence (50%) of the recurrent codon 571 variant (p.E571K) was observed in GEP-defined PMBL and was associated with shorter PFS. Age, International Prognostic Index and bulky mass were similar in XPO1 mutant and wild-type cases. KPT-185 induced a dose-dependent decrease in cell proliferation and increased cell-death in PMBL cell lines harboring wild type or XPO1 E571K mutant alleles. Experiments in transfected U2OS cells further confirmed that the XPO1 E571K mutation does not have a drastic impact on KPT-330 binding. To conclude the XPO1 E571K mutation represents a genetic hallmark of the PMBL subtype and serves as a new relevant PMBL biomarker. SINE compounds appear active for both mutated and wild-type protein. Am. J. Hematol. 91:923-930, 2016. © 2016 Wiley Periodicals, Inc.

Published
2016
Full Text
View/download PDF

208. Prévalence, cinétique et valeur pronostique de la mutation XPO1 E571K dans le lymphome de Hodgkin

Author

Camus, Vincent, UNIROUEN - UFR Santé (UNIROUEN UFR Santé), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU), and Fabrice Jardin

Subjects
ADN plasmatique, Lymphome de Hodgkin, Exportin-1 (XPO1), PCR digitale, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

Le lymphome de Hodgkin classique (LHc) est un des lymphomes les plus fréquents et partage de nombreuses caractéristiques cliniques et génétiques avec le lymphome B diffus à grandes cellules primitif du médiastin (PMBL). Dans la présente étude rétrospective, nous avons analysé une mutation récurrente de type hotspot du gène de l’exportin 1 (XPO1, p.E571K), précédemment identifiée dans les PMBL, dans une large série de biopsies et plasmas de patients diagnostiqués avec un LHc en première ligne de traitement, en utilisant une technique hautement sensible de PCR digitale (PCRd). 94 patients ont ainsi été inclus dans cette étude. La mutation XPO1 E571K est retrouvée à une fréquence élevée, dans environ un quart des patients de notre étude (24,2%). Les patients mutés et non-mutés présentaient des caractéristiques cliniques similaires. Les patients avec une mutation restant détectable dans le plasma en fin de traitement avaient tendance à rechuter davantage que les patients dont la mutation était devenue indétectable dans le plasma en fin de traitement (PFS à deux ans = 57,1%, IC95% : 30,1%-100% versus PFS à 2 ans =90,5%, IC95% : 78,8%-100% respectivement, p=0,0601). En conclusion, la détection de la mutation XPO1 E571K dans l’ADN extrait de la biopsie et du plasma par PCRd pourrait servir de nouveau biomarqueur dans le LHc, au moment du diagnostic et au cours du suivi de la maladie résiduelle. La détection de cette mutation dans le plasma des patients représente un saut technologique majeur dans la prise en charge du LHc.

Published
2016

209. Dépression résistante : les autres stratégies thérapeutiques

Author

Saba, Ghassen, Nieto, Isabel, Bation, Rémy, Allaïli, Najib, Bennabi, Djamila, Moliere, Fanny, Richieri, Raphaëlle, Holtzmann, Jérôme, Bubrovszky, Maxime, Camus, Vincent, Charpeaud, Thomas, Courtet, Philippe, Courvoisier, Pierre, Haesebaert, Frédéric, Doumy, Olivier, El-Hage, Wissam, Garnier, Marion, D'Amato, Thierry, Bougerol, Thierry, Lançon, Christophe, Haffen, Emmanuel, Llorca, Pierre-Michel, Vaiva, Guillaume, Bellivier, Frank, Leboyer, Marion, Aouizerate, Bruno, Pôle de Psychiatrie [Hôpital Henri Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital H. Mondor - A. Chenevier, Fondation FondaMental [Créteil], Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier le Vinatier [Bron], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Pôle Psychiatrie et Neurologie [Grenoble], Centre Hospitalier Universitaire [Grenoble] (CHU), Service de Psychiatrie [CHRU Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Hôpital Michel Fontan 1, Clinique Psychiatrique Universitaire [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), CHU Clermont-Ferrand, Neuropsychiatrie : recherche épidémiologique et clinique (PSNREC), Université Montpellier 1 (UM1)-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Charles Perrens, and Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)

Subjects
Depressive Disorder, S-Adenosylmethionine, Monoamine Oxidase Inhibitors, Drug Resistance, Antidepressive Agents, Food-Drug Interactions, Folic Acid, Double-Blind Method, Dietary Supplements, Dopamine Agonists, Fatty Acids, Omega-3, Humans, Central Nervous System Stimulants, Drug Interactions, Drug Therapy, Combination, Ketamine, Adrenergic alpha-Agonists, Excitatory Amino Acid Antagonists, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Randomized Controlled Trials as Topic
Abstract

International audience; Non-selective and irreversible MAOI have become as third or fourth-line strategy for the management of treatment-resistant depression. Non-selective and irreversible MAOI requires careful monitoring of drug interactions and dietary restrictions. Nutritional supplements such as omega-3 have been found to produce beneficial effects in the management of treatment-resistant depression when administered in combination with the ongoing antidepressant treatment. The glutamate antagonist ketamine has been found to produce beneficial effects in the management of treatment-resistant depression while administered alone. Dopamine and/or norepinephrine agonists, such as methylphenidate, modafinil or pramipexole, have been found to produce beneficial effects in the management of treatment-resistant depression when administered in combination with the ongoing antidepressant treatment.

Published
2016
Full Text
View/download PDF

210. Resistant depression : Switching and combining strategies of ă antidepressant medications

Author

Charpeaud, Thomas, Moliere, Fanny, Bubrovszky, Maxime, Haesebaert, Frederic, Allaïli, Najib, Bation, Remy, Nieto, Isabel, Richieri, Raphaëlle, Saba, Ghassen, Bellivier, Frank, Bennabi, Djamila, Holtzmann, Jerome, Camus, Vincent, Courtet, Philippe, Courvoisier, Pierre, d'Amato, Thierry, Doumy, Olivier, Garnier, Marion, Bougerol, Thierry, Lançon, Christophe, Haffen, Emmanuel, Leboyer, Marion, Llorca, Pierre-Michel, Vaiva, Guillaume, El-Hage, Wissam, Aouizerate, Bruno, Fondation FondaMental [Créteil], CHU Gabriel Montpied (CHU), CHU Clermont-Ferrand, Laboratoire de Neurosciences Fonctionnelles et Pathologies (LNFP), Université de Lille, Droit et Santé-Centre National de la Recherche Scientifique (CNRS), Centre de neuroImagerie de Recherche, Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-CHU Pitié-Salpêtrière [APHP], Laboratoire de santé publique évaluation des systèmes de soins et santé perçue, Pôle de Psychiatrie 'Solaris', Service Pr. Naudin, Centre Hospitalier Universitaire de Sainte-Marguerite, INSERM U955, équipe 15, Service de psychiatrie, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Henri Mondor-Hôpital Albert Chenevier-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Henri Mondor-Hôpital Albert Chenevier-Réseau de coopération scientifique en santé mentale, Fondation FondaMental [Créteil]-Fondation FondaMental [Créteil]-Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Optimisation Thérapeutique en Neuropsychopharmacologie (VariaPsy - U1144), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Diderot - Paris 7 (UPD7), Cognition, Action, et Plasticité Sensorimotrice [Dijon - U1093] (CAPS), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM), UNIROUEN - UFR Santé (UNIROUEN UFR Santé), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU), Neuropsychiatrie : recherche épidémiologique et clinique, Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Université Grenoble Alpes - UFR Médecine (UGA UFRM), Université Grenoble Alpes (UGA), Vulnérabilité à la schizophrénie : des bases neurobiologiques à la thérapeutique, Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-IFR19-Centre Hospitalier le Vinatier [Bron], Clinique Universitaire de Psychiatrie, CHU Grenoble, Service de Psychiatrie, Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Interdisciplinary Institute for Neuroscience (IINS), Université de Bordeaux (UB)-Centre National de la Recherche Scientifique (CNRS), Service de psychiatrie adulte - B, Pôle de Psychiatrie, Faculté de Médecine-IFR10-Groupe hospitalier Henri Mondor-Albert Chenevier, Clinique Psychiatrique Universitaire [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Imagerie et cerveau, Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Charles Perrens, CHU Gabriel Montpied [Clermont-Ferrand], Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Département Universitaire de Psychiatrie - [Hôpital Sainte Marguerite - APHM] (Hôpitaux Sud), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud ), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Hôpital Albert Chenevier-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Hôpital Albert Chenevier-Réseau de coopération scientifique en santé mentale, Variabilité de réponse aux Psychotropes (VariaPsy - U1144), Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Neuropsychiatrie : recherche épidémiologique et clinique (PSNREC), Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Imagerie et cerveau (iBrain - Inserm U1253 - UNIV Tours ), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Fondation Fondamental, CHU Gabriel Montpied ( CHU ), Laboratoire de Neurosciences Fonctionnelles et Pathologies ( LNFP ), Université de Lille, Droit et Santé-Centre National de la Recherche Scientifique ( CNRS ), Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute ( ICM ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -CHU Pitié-Salpêtrière [APHP]-Centre National de la Recherche Scientifique ( CNRS ), Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Henri Mondor-Hôpital Albert Chenevier-Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Henri Mondor-Hôpital Albert Chenevier-Réseau de coopération scientifique en santé mentale, Fondation FondaMental [Créteil]-Fondation FondaMental [Créteil]-Institut Mondor de Recherche Biomédicale ( IMRB ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), Variabilité de réponse aux psychotropes ( VariaPsy - U1144 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Paris Diderot - Paris 7 ( UPD7 ), Cognition, Action, et Plasticité Sensorimotrice [Dijon - U1093] ( CAPS ), Université de Bourgogne ( UB ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), UNIROUEN - UFR Santé, Université de Rouen Normandie ( UNIROUEN ), Normandie Université ( NU ) -Normandie Université ( NU ), Université Montpellier 1 ( UM1 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université de Montpellier ( UM ), Université Grenoble Alpes - UFR Médecine ( UGA UFRM ), Université Grenoble Alpes ( UGA ), Centre Hospitalier le Vinatier [Bron]-IFR19-Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon, Institut Mondor de Recherche Biomédicale ( IMRB ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), Fondation FondaMental, Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), Institut Interdisciplinaire de Neurosciences ( IINS ), Université Bordeaux Segalen - Bordeaux 2-Centre National de la Recherche Scientifique ( CNRS ), CHRU Tours, Université de Tours-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Centre hospitalier Charles Perrens [Bordeaux], Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ) -CHU Pitié-Salpêtrière [APHP], Université Paris Diderot - Paris 7 ( UPD7 ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud )-Assistance Publique - Hôpitaux de Marseille (APHM)-Aix Marseille Université (AMU), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-IFR10-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-IFR10, Centre Hospitalier le Vinatier [Bron]-IFR19-Université Claude Bernard Lyon 1 (UCBL), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-IFR10, Centre National de la Recherche Scientifique (CNRS)-Université de Bordeaux (UB), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Descartes - Paris 5 (UPD5), Université Montpellier 1 (UM1)-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Tours (UT), and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)

Subjects
[ SHS.PSY ] Humanities and Social Sciences/Psychology, [ SDV.MHEP.PSM ] Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, [SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, Quality of Life, [ SHS.ECO ] Humanities and Social Sciences/Economies and finances, [SHS.PSY]Humanities and Social Sciences/Psychology, [ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, [SHS.ECO]Humanities and Social Sciences/Economics and Finance
Abstract

International audience; Switching antidepressant medication may be helpful in depressed patients ă having no benefit from the initial antidepressant treatment. ă Before considering switching strategy, the initial antidepressant ă treatment should produce no therapeutic effect after at least 4 weeks of ă administration at adequate dosage. ă Choosing an antidepressant of pharmacologically distinct profile fails ă to consistently demonstrate a significant superiority in terms of ă effectiveness over the switching to another antidepressant within the ă same pharmacological class. ă Augmenting SSRI/SNRIs with mirtazapine/mianserin has become the most ă recommended strategy of antidepressant combinations. ă Augmenting SSRI with tricyclic drugs is now a less recommended strategy ă of antidepressant combinations given the increased risk for the ă occurrence of pharmacokinetic drug-drug interactions and adverse ă effects.

Published
2016
Full Text
View/download PDF

211. Resistant depression : potentiation strategies

Author

Doumy, Olivier, Bennabi, Djamila, El-Hage, Wissam, Allaïli, Najib, Bation, Remy, Bellivier, Frank, Holtzmann, Jerome, Bubrovszky, Maxime, Camus, Vincent, Charpeaud, Thomas, Courvoisier, Pierre, D'Amato, Thierry, Garnier, Marion, Haesebaert, Frederic, Bougerol, Thierry, Lançon, Christophe, Moliere, Fanny, Nieto, Isabel, Richieri, Raphaëlle, Saba, Ghassen, Courtet, Philippe, Vaiva, Guillaume, Leboyer, Marion, Llorca, Pierre-Michel, Aouizerate, Bruno, Haffen, Emmanuel, Cognition, Action, et Plasticité Sensorimotrice [Dijon - U1093] (CAPS), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM), Clinique Psychiatrique Universitaire [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Imagerie et cerveau (iBrain - Inserm U1253 - UNIV Tours ), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de neuroImagerie de Recherche, Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Variabilité de réponse aux Psychotropes (VariaPsy - U1144), Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire de Neurosciences Fonctionnelles et Pathologies (LNFP), Université de Lille, Droit et Santé-Centre National de la Recherche Scientifique (CNRS), UNIROUEN - UFR Santé (UNIROUEN UFR Santé), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU), Fondation FondaMental [Créteil], CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand, Université Grenoble Alpes - UFR Médecine (UGA UFRM), Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Vulnérabilité à la schizophrénie : des bases neurobiologiques à la thérapeutique, Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-IFR19-Centre Hospitalier le Vinatier [Bron], Clinique Universitaire de Psychiatrie, CHU Grenoble, Service de Psychiatrie, Département Universitaire de Psychiatrie - [Hôpital Sainte Marguerite - APHM] (Hôpitaux Sud), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud ), Laboratoire de santé publique évaluation des systèmes de soins et santé perçue, INSERM U955, équipe 15, Service de psychiatrie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Hôpital Albert Chenevier-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Hôpital Albert Chenevier-Réseau de coopération scientifique en santé mentale, Fondation FondaMental [Créteil]-Fondation FondaMental [Créteil]-Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Neuropsychiatrie : recherche épidémiologique et clinique (PSNREC), Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Pôle de Psychiatrie, Faculté de Médecine-IFR10-Groupe hospitalier Henri Mondor-Albert Chenevier, Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Interdisciplinary Institute for Neuroscience (IINS), Université de Bordeaux (UB)-Centre National de la Recherche Scientifique (CNRS), Service de psychiatrie adulte - B, Centre hospitalier Charles Perrens [Bordeaux], Imagerie et cerveau, Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-CHU Pitié-Salpêtrière [APHP], Optimisation Thérapeutique en Neuropsychopharmacologie (VariaPsy - U1144), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Diderot - Paris 7 (UPD7), CHU Gabriel Montpied (CHU), Université Grenoble Alpes (UGA), Pôle de Psychiatrie 'Solaris', Service Pr. Naudin, Centre Hospitalier Universitaire de Sainte-Marguerite, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Henri Mondor-Hôpital Albert Chenevier-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Henri Mondor-Hôpital Albert Chenevier-Réseau de coopération scientifique en santé mentale, Neuropsychiatrie : recherche épidémiologique et clinique, Hôpital Charles Perrens, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Hospitalier le Vinatier [Bron]-IFR19-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud )-Assistance Publique - Hôpitaux de Marseille (APHM)-Aix Marseille Université (AMU), Université Montpellier 1 (UM1)-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Cognition, Action, et Plasticité Sensorimotrice [Dijon - U1093] ( CAPS ), Université de Bourgogne ( UB ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), CHRU Tours, Université de Tours-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute ( ICM ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ) -CHU Pitié-Salpêtrière [APHP], Variabilité de réponse aux psychotropes ( VariaPsy - U1144 ), Université Paris Diderot - Paris 7 ( UPD7 ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Laboratoire de Neurosciences Fonctionnelles et Pathologies ( LNFP ), Université de Lille, Droit et Santé-Centre National de la Recherche Scientifique ( CNRS ), UNIROUEN - UFR Santé, Université de Rouen Normandie ( UNIROUEN ), Normandie Université ( NU ) -Normandie Université ( NU ), Fondation Fondamental, CHU Gabriel Montpied ( CHU ), Université Grenoble Alpes - UFR Médecine ( UGA UFRM ), Université Grenoble Alpes ( UGA ), Centre Hospitalier le Vinatier [Bron]-IFR19-Université Claude Bernard Lyon 1 ( UCBL ), Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Henri Mondor-Hôpital Albert Chenevier-Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Henri Mondor-Hôpital Albert Chenevier-Réseau de coopération scientifique en santé mentale, Fondation FondaMental [Créteil]-Fondation FondaMental [Créteil]-Institut Mondor de Recherche Biomédicale ( IMRB ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), Université Montpellier 1 ( UM1 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université de Montpellier ( UM ), Institut Mondor de Recherche Biomédicale ( IMRB ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), Fondation FondaMental, Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), Institut Interdisciplinaire de Neurosciences ( IINS ), Université Bordeaux Segalen - Bordeaux 2-Centre National de la Recherche Scientifique ( CNRS ), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Tours (UT), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Descartes - Paris 5 (UPD5), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -CHU Pitié-Salpêtrière [APHP]-Centre National de la Recherche Scientifique ( CNRS ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Paris Diderot - Paris 7 ( UPD7 ), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-IFR10-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-IFR10, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-IFR10, and Centre National de la Recherche Scientifique (CNRS)-Université de Bordeaux (UB)

Subjects
[ SHS.PSY ] Humanities and Social Sciences/Psychology, [ SDV.MHEP.PSM ] Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, [SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, Quality of Life, [ SHS.ECO ] Humanities and Social Sciences/Economies and finances, [SHS.PSY]Humanities and Social Sciences/Psychology, [ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, [SHS.ECO]Humanities and Social Sciences/Economics and Finance
Abstract

International audience; Lithium is among the most classically recommended add-on therapeutic ă strategy for the management of depressive patients showing unsuccessful ă response to standard antidepressant medications. ă The effectiveness of the add-on strategy with lithium requires achieving ă plasma levels above 0.5 mEq/L. ă Mood-stabilizing antiepileptic drugs such as carbamazepine, valproate ă derivatives or lamotrigine have not demonstrated conclusive therapeutic ă effects for the management of depressive patients showing unsuccessful ă response to standard antidepressant medications. ă Thyroid hormones are considered among the currently recommended add-on ă therapeutic strategy for the management of depressive patients showing ă unsuccessful response to standard antidepressant medications. ă The effectiveness of the add-on strategy with thyroid hormones requires ă achieving plasma concentration of TSH close to the lower limits at the ă normal range (0.4 mUI/L) or even below it. Second-generation ă antipsychotics such as aripiprazole or quetiapine have consistently ă demonstrated significant therapeutic effects for the management of ă depressive patients showing unsuccessful response to standard ă antidepressant medications. ă Second-generation antipsychotics however require the careful monitoring ă of both cardiovascular and metabolic adverse effects.

Published
2016
Full Text
View/download PDF

212. Détection de mutations somatiques dans l’ADN circulant plasmatique par séquençage de nouvelle génération (NGS) : première étape vers une validation du concept de biopsie liquide dans le lymphome primitif du système nerveux central

Author

Bohers, Elodie, Fontanilles, Maxime, Viailly, Pierre Julien, Marguet, Florent, Bertrand, Philippe, Dubois, Sydney, Camus, Vincent, Ruminy, Philippe, Tilly, Herve, Picquenot, Jean Michel, Laquerriere, Annie, Jardin, Fabrice, Bohers, Elodie, Groupe d'étude des proliférations lymphoïdes (GPL), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU), Génomique et Médecine Personnalisée du Cancer et des Maladies Neuropsychiatriques (GPMCND), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'Anatomie et Cytologie Pathologique [CHU Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), Endothélium microcirculatoire cérébral et lésions du système nerveux central au cours du développement (Néovasc), Normandie Université (NU)-Normandie Université (NU)-Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université (NU)-Normandie Université (NU)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Rouen Normandie (UNIROUEN), and Normandie Université (NU)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio]
Abstract

International audience; IntroductionLes lymphomes primitifs du système nerveux central (PCNSL) sont des tumeurs rares du cerveau dont le diagnostic est complexe mais essentiel pour leur prise en charge thérapeutique. Des études récentes, dans différents types de cancers, ont montré l’intérêt de l’ADN circulant plasmatique comme méthode non invasive de détection de matériel génomique tumoral. L’objectif de cette étude était de déterminer si le séquençage ciblé de l’ADN plasmatique permettait de détecter les mutations somatiques présentes dans la tumeur chez des patients atteints d’un PCNSL.Patients et méthodesNous avons constitué une cohorte rétrospective de 30 PCNSL pour lesquels nous disposions d’ADN tumoral au diagnostic. Ces ADN ont été séquencés à l’aide du PGM ® (Life technologies) en utilisant un lymphopanel de 34 gènes. Afin d’améliorer la sensibilité du séquençage de l’ADN circulant (extrait des 24 plasmas disponibles, ADNp), les mutations somatiques identifiées dans la tumeur ont été recherchées en ciblant spécifiquement les amplicons d’intérêt. RésultatsParmi les 30 échantillons tumoraux, 21 (70%) ont été classés selon l’algorithme de Hans en sous type non GC, 8 (27%) en sous type GC et 1 non classé (3%). 29 tumeurs présentaient au moins une mutation somatique, le plus souvent un variant nucléotidique non synonyme, avec une fréquence allélique (VAF) moyenne de 46% [8%-91%]. Les profils mutationnels identifiés étaient, pour la majorité d’entre eux, caractéristiques du sous type ABC, affectant principalement les voies NF-kB et du BCR : MYD88 (n=23, 77%), PIM1 (n=11, 37%), CD79B (n=10, 33%) et TNFAIP3 (n=6, 20%). Parmi les 23 tumeurs présentant une mutation de MYD88, la L265P était la plus fréquente (20 patients, 67%) et 8 présentaient une double altération de CD79B et MYD88 (toujours la L265P). L’analyse des variations du nombre de copies de gènes a montré des délétions et gains de copie pour 29 patients dont 23 cas avec des délétions de CDKN2A/2B (77%). Les 24 plasmas disponibles présentaient de l’ADN circulant (concentration moyenne = 64 ng/mL plasma) mais aucune corrélation n’a pu être établie entre le volume tumoral et la concentration d’ADNp. Treize (54%) de ces ADNp avaient au moins une mutation détectable, avec une VAF moyenne de 4% [0.1%-28%]. Nous n’avons pas observé de différence significative de survie globale entre les patients avec ou sans mutation identifiée dans l’ADN circulant (OS 27 mois vs OS 18 mois ; p=0.3). Pour 10 des 17 patients présentant la mutation L265P dans la tumeur et avec un échantillon de plasma disponible, nous avons pu retrouver cette mutation dans l’ADNp, ce qui en fait un biomarqueur circulant potentiel intéressant.ConclusionCette étude montre pour la première fois la possibilité de détecter des mutations somatiques dans l’ADN circulant plasmatique de patients atteints d’un PCNSL, constituant ainsi un outil peu invasif qui pourrait aider au diagnostic de ces pathologies. Etant donné la récurrence des mutations de MYD88, CD79B et PIM1 dans la tumeur, un test est actuellement en cours de développement pour rechercher spécifiquement ces altérations dans l’ADNp des PCNSL. Des études complémentaires permettront d’augmenter la valeur prédictive de ce nouvel outil prometteur pour la prise en charge des PCNSL.

Published
2016

213. Benzodiazepine use and neuroimaging markers of Alzheimer’s disease in nondemented older individuals: an MRI and 18F Florbetapir PET study in the MEMENTO cohort

Author

Gallet, Quentin, Bouteloup, Vincent, Locatelli, Maxime, Habert, Marie-Odile, Chupin, Marie, Delrieu, Julien, Lebouvier, Thibaud, Robert, Gabriel, David, Renaud, Bulteau, Samuel, Balageas, Anna-Chloé, Surget, Alexandre, Belzung, Catherine, Arlicot, Nicolas, Ribeiro, Maria-Joao, Barantin, Laurent, Andersson, Frédéric, Cottier, Jean-Philippe, Gissot, Valérie, El-Hage, Wissam, Camus, Vincent, Gohier, Bénédicte, and Desmidt, Thomas

Abstract

Recent evidence suggests an association between benzodiazepines (BZDs) use and lower brain amyloid load, a hallmark of AD pathophysiology. Other AD-related markers include hippocampal atrophy, but the effect of BZDs on hippocampal volume remains unclear. We aimed at 1) replicating findings on BZDs use and brain amyloid load and 2) investigating associations between BZDs use and hippocampal volume, in the MEMENTO clinical cohort of nondemented older adults with isolated memory complaint or light cognitive impairment at baseline. Total Standardized Uptake Value Ratio (SUVR) of brain amyloid load and hippocampal volume (HV) were obtained, respectively, from 18F Florbetapir positron emission tomography (PET) and magnetic resonance imaging (MRI), and compared between BZD chronic users and nonusers using multiple linear regressions adjusted for age, sex, educational level, ApoE ε4 genotype, cognitive and neuropsychiatric assessments, history of major depressive episodes and antidepressant intake. BZD users were more likely to manifest symptoms of depression, anxiety and apathy. In the MRI subgroup, BZD users were also more frequently females with low education and greater clinical impairments as assessed with the clinical dementia rating scale. Short- versus long-acting BZDs, Z-drugs versus non-Z-drugs BZDs, as well as dose and duration of BZD use, were also considered in the analyses. Total SUVR and HV were significantly lower and larger, respectively, in BZD users (n= 38 in the PET subgroup and n= 331 in the MRI subgroup) than in nonusers (n= 251 in the PET subgroup and n= 1840 in the MRI subgroup), with a medium (Cohen’s d = −0.43) and low (Cohen’s d = 0.10) effect size, respectively. Short-acting BZDs and Z-drugs were more significantly associated with larger HV. We found no effect of dose and duration of BZD use. Our results support the involvement of the GABAergic system as a potential target for blocking AD-related pathophysiology, possibly via reduction in neuronal activity and neuroinflammation. Future longitudinal studies may confirm the causal effect of BZDs to block amyloid accumulation and hippocampal atrophy.

Published
2021
Full Text
View/download PDF

215. Sleep and mood changes in advanced age after blue-blocking (yellow) intra ocular lens (IOLs) implantation during cataract surgical treatment: a randomized controlled trial

Author

Zambrowski, Olivia, primary, Tavernier, Elsa, additional, Souied, Eric H, additional, Desmidt, Thomas, additional, Le Gouge, Amélie, additional, Bellicaud, David, additional, Cochener, Béatrice, additional, Limousin, Nadège, additional, Hommet, Caroline, additional, Autret-Leca, Elisabeth, additional, Pisella, Pierre-Jean, additional, and Camus, Vincent, additional

Published
2017
Full Text
View/download PDF

216. Brain Tissue Pulsatility is Increased in Midlife Depression: a Comparative Study Using Ultrasound Tissue Pulsatility Imaging

Author

Desmidt, Thomas, primary, Brizard, Bruno, additional, Dujardin, Paul-Armand, additional, Ternifi, Redouane, additional, Réméniéras, Jean-Pierre, additional, Patat, Frédéric, additional, Andersson, Frédéric, additional, Cottier, Jean-Philippe, additional, Vierron, Emilie, additional, Gissot, Valérie, additional, Kim, Kang, additional, Aizenstein, Howard, additional, El-Hage, Wissam, additional, and Camus, Vincent, additional

Published
2017
Full Text
View/download PDF

217. Non-invasive detection of somatic mutations using next-generation sequencing in primary central nervous system lymphoma

Author

Fontanilles, Maxime, primary, Marguet, Florent, additional, Bohers, Élodie, additional, Viailly, Pierre-Julien, additional, Dubois, Sydney, additional, Bertrand, Philippe, additional, Camus, Vincent, additional, Mareschal, Sylvain, additional, Ruminy, Philippe, additional, Maingonnat, Catherine, additional, Lepretre, Stéphane, additional, Veresezan, Elena-Liana, additional, Derrey, Stéphane, additional, Tilly, Hervé, additional, Picquenot, Jean-Michel, additional, Laquerrière, Annie, additional, and Jardin, Fabrice, additional

Published
2017
Full Text
View/download PDF

222. Ultrasound Tissue Pulsatility Imaging Suggests Impairment in Global Brain Pulsatility and Small Vessels in Elderly Patients with Orthostatic Hypotension

Author

Biogeau, Julie, primary, Desmidt, Thomas, additional, Dujardin, Paul-Armand, additional, Ternifi, Redouane, additional, Eudo, Charlotte, additional, Vierron, Emilie, additional, Remenieras, Jean-Pierre, additional, Patat, Frédéric, additional, Camus, Vincent, additional, and Constans, Thierry, additional

Published
2017
Full Text
View/download PDF

224. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis

Author

Jansen, Willemijn J, Ossenkoppele, Rik, Knol, Dirk L, Tijms, Betty M, Scheltens, Philip, Verhey, Frans RJ, Visser, Pieter Jelle, Amyloid Biomarker Study Group, Aalten, Pauline, Aarsland, Dag, Alcolea, Daniel, Alexander, Myriam, Almdahl, Ina S, Arnold, Steven E, Baldeiras, Inês, Barthel, Henryk, van Berckel, Bart NM, Bibeau, Kristen, Blennow, Kaj, Brooks, David J, van Buchem, Mark A, Camus, Vincent, Cavedo, Enrica, Chen, Kewei, Chetelat, Gael, Cohen, Ann D, Drzezga, Alexander, Engelborghs, Sebastiaan, Fagan, Anne M, Fladby, Tormod, Fleisher, Adam S, van der Flier, Wiesje M, Ford, Lisa, Förster, Stefan, Fortea, Juan, Foskett, Nadia, Frederiksen, Kristian S, Freund-Levi, Yvonne, Frisoni, Giovanni B, Froelich, Lutz, Gabryelewicz, Tomasz, Gill, Kiran Dip, Gkatzima, Olymbia, Gómez-Tortosa, Estrella, Gordon, Mark Forrest, Grimmer, Timo, Hampel, Harald, Hausner, Lucrezia, Hellwig, Sabine, Herukka, Sanna-Kaisa, Hildebrandt, Helmut, Ishihara, Lianna, Ivanoiu, Adrian, Jagust, William J, Johannsen, Peter, Kandimalla, Ramesh, Kapaki, Elisabeth, Klimkowicz-Mrowiec, Aleksandra, Klunk, William E, Köhler, Sebastian, Koglin, Norman, Kornhuber, Johannes, Kramberger, Milica G, Van Laere, Koen, Landau, Susan M, Lee, Dong Young, de Leon, Mony, Lisetti, Viviana, Lleó, Alberto, Madsen, Karine, Maier, Wolfgang, Marcusson, Jan, Mattsson, Niklas, de Mendonça, Alexandre, Meulenbroek, Olga, Meyer, Philipp T, Mintun, Mark A, Mok, Vincent, Molinuevo, José Luis, Møllergård, Hanne M, Morris, John C, Mroczko, Barbara, Van der Mussele, Stefan, Na, Duk L, Newberg, Andrew, Nordberg, Agneta, Nordlund, Arto, Novak, Gerald P, Paraskevas, George P, Parnetti, Lucilla, Perera, Gayan, Peters, Oliver, Popp, Julius, Prabhakar, Sudesh, Rabinovici, Gil D, Ramakers, Inez HGB, Rami, Lorena, Resende de Oliveira, Catarina, and Rinne, Juha O

Subjects
Adult, Male, Aging, Genotype, Apolipoprotein E4, and over, Neurodegenerative, Alzheimer's Disease, Medical and Health Sciences, Risk Factors, Clinical Research, General & Internal Medicine, mental disorders, Prevalence, 80 and over, Acquired Cognitive Impairment, Genetics, Humans, 2.1 Biological and endogenous factors, Cognitive Dysfunction, Aetiology, Amyloid Biomarker Study Group, Cerebrospinal Fluid, Aged, screening and diagnosis, Amyloid beta-Peptides, Prevention, Age Factors, Neurosciences, Brain, Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD), Middle Aged, Brain Disorders, Detection, Positron-Emission Tomography, Neurological, Dementia, Female, Biomarkers, 4.2 Evaluation of markers and technologies
Abstract

ImportanceCerebral amyloid-β aggregation is an early pathological event in Alzheimer disease (AD), starting decades before dementia onset. Estimates of the prevalence of amyloid pathology in persons without dementia are needed to understand the development of AD and to design prevention studies.ObjectiveTo use individual participant data meta-analysis to estimate the prevalence of amyloid pathology as measured with biomarkers in participants with normal cognition, subjective cognitive impairment (SCI), or mild cognitive impairment (MCI).Data sourcesRelevant biomarker studies identified by searching studies published before April 2015 using the MEDLINE and Web of Science databases and through personal communication with investigators.Study selectionStudies were included if they provided individual participant data for participants without dementia and used an a priori defined cutoff for amyloid positivity.Data extraction and synthesisIndividual records were provided for 2914 participants with normal cognition, 697 with SCI, and 3972 with MCI aged 18 to 100 years from 55 studies.Main outcomes and measuresPrevalence of amyloid pathology on positron emission tomography or in cerebrospinal fluid according to AD risk factors (age, apolipoprotein E [APOE] genotype, sex, and education) estimated by generalized estimating equations.ResultsThe prevalence of amyloid pathology increased from age 50 to 90 years from 10% (95% CI, 8%-13%) to 44% (95% CI, 37%-51%) among participants with normal cognition; from 12% (95% CI, 8%-18%) to 43% (95% CI, 32%-55%) among patients with SCI; and from 27% (95% CI, 23%-32%) to 71% (95% CI, 66%-76%) among patients with MCI. APOE-ε4 carriers had 2 to 3 times higher prevalence estimates than noncarriers. The age at which 15% of the participants with normal cognition were amyloid positive was approximately 40 years for APOE ε4ε4 carriers, 50 years for ε2ε4 carriers, 55 years for ε3ε4 carriers, 65 years for ε3ε3 carriers, and 95 years for ε2ε3 carriers. Amyloid positivity was more common in highly educated participants but not associated with sex or biomarker modality.Conclusions and relevanceAmong persons without dementia, the prevalence of cerebral amyloid pathology as determined by positron emission tomography or cerebrospinal fluid findings was associated with age, APOE genotype, and presence of cognitive impairment. These findings suggest a 20- to 30-year interval between first development of amyloid positivity and onset of dementia.

Published
2015

225. 18F-FDG-PET/CT Imaging in Patients with Febrile Neutropenia and Haematological Malignancies

Author

Camus, Vincent, Edet-Sanson, Agathe, Bubenheim, Michael, Hitzel, Anne, Becker, Stéphanie, David, Marion, Stamatoullas, Aspasia, Lenain, Pascal, Jardin, Fabrice, Contentin, Nathalie, Fontoura, Marie Laure, Cardinael, Nathalie, Vaudaux, Sandrine, Dubois, Sydney, Tilly, Hervé, Vera, Pierre, Leprêtre, Stéphane, Service d'Hématologie, Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), Service de médecine nucléaire [Rouen], CRLCC Haute Normandie-Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), Unité de biostatistiques [CHU Rouen], Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU), Service de Médecine Nucléaire [Toulouse], CHU Toulouse [Toulouse], Equipe Quantification en Imagerie Fonctionnelle (QuantIF-LITIS), Laboratoire d'Informatique, de Traitement de l'Information et des Systèmes (LITIS), Institut national des sciences appliquées Rouen Normandie (INSA Rouen Normandie), Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Université Le Havre Normandie (ULH), Normandie Université (NU)-Institut national des sciences appliquées Rouen Normandie (INSA Rouen Normandie), Groupe d'étude des proliférations lymphoïdes (GPL), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Unité de recherche clinique [CHU Rouen], CHU Rouen, and Normandie Université (NU)-Normandie Université (NU)

Subjects
[SDV]Life Sciences [q-bio]
Abstract

International audience; The aim of the present study was to assess the prevalence of hyper-metabolic infection sites revealed by fluorine-18 ((18)F) fluorodeoxyglucose (FDG) positron-emission tomography (PET) combined with computed tomography (CT) in patients with febrile neutropenia (FN). Forty-eight consecutive patients with haematological malignancies and persistent FN (temperature ≥38°C and neutrophil count

Published
2015

226. Intérêt de la TEP-FDG (tomodensitométrie par émission de positons au Fluorodeoxyglucose) dans l’exploration des neutropénies fébriles induites par une chimiothérapie dans le cadre d’une hémopathie maligne

Author

Camus, Vincent, Edet-Sanson, Agathe, Bubenheim, Michael, Hitzel, Anne, Becker, Stéphanie, David, Marion, Stamatoullas, Aspasia, Lenain, Pascal, Jardin, Fabrice, Contentin, Nathalie, Fontoura, Marie-Laure, Cardinael, Nathalie, vaudaux, sandrine, Dubois, Sydney, Tilly, Hervé, Vera, Pierre, Leprêtre, Stéphane, Service d'Hématologie, Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), Equipe Quantification en Imagerie Fonctionnelle (QuantIF-LITIS), Laboratoire d'Informatique, de Traitement de l'Information et des Systèmes (LITIS), Institut national des sciences appliquées Rouen Normandie (INSA Rouen Normandie), Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Université Le Havre Normandie (ULH), Normandie Université (NU)-Institut national des sciences appliquées Rouen Normandie (INSA Rouen Normandie), Normandie Université (NU), Service de médecine nucléaire [Rouen], CRLCC Haute Normandie-Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), Unité de biostatistiques [CHU Rouen], Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Service de Médecine Nucléaire [Toulouse], CHU Toulouse [Toulouse], Laboratoire de biologie clinique [Rouen], Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel)-Université de Rouen Normandie (UNIROUEN), Groupe d'étude des proliférations lymphoïdes (GPL), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Unité de recherche clinique [CHU Rouen], CHU Rouen, and Normandie Université (NU)-Normandie Université (NU)

Subjects
[SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2015

227. Prevalence of cerebral amyloid pathology in persons without dementia

Author

Jansen, Willemijn J., Ossenkoppele, Rik, Knol, Dirk L., Tijms, Betty M., Scheltens, Philip, Verhey, Frans R. J., Visser, Pieter Jelle, Aalten, Pauline, Aarsland, Dag, Alcolea, Daniel, Alexander, Myriam, Roe, Catherine M., Rot, Uros, Rowe, Christopher C., Rüther, Eckart, Sabri, Osama, Sanchez-Juan, Páscual, Santana, Isabel, Sarazin, Marie, Schröder, Johannes, Schütte, Christin, Almdahl, Ina S., Seo, Sang W., Soetewey, Femke, Soininen, Hilkka, Spiru, Luiza, Struyfs, Hanne, Teunissen, Charlotte E., Tsolaki, Magda, Vandenberghe, Rik, Verbeek, Marcel M., Villemagne, Victor L., Arnold, Steven E., Vos, Stephanie J. B., van Waalwijk van Doorn, Linda J. C., Waldemar, Gunhild, Wallin, Anders, Wallin, Åsa K., Wiltfang, Jens, Wolk, David A., Zboch, Marzena, Zetterberg, Henrik, Baldeiras, Inês, Barthel, Henryk, van Berckel, Bart N. M., Bibeau, Kristen, Blennow, Kaj, Brooks, David J., van Buchem, Mark A., Camus, Vincent, Cavedo, Enrica, Chen, Kewei, Chetelat, Gael, Cohen, Ann D., Drzezga, Alexander, Engelborghs, Sebastiaan, Fagan, Anne M., Fladby, Tormod, Fleisher, Adam S., van der Flier, Wiesje M., Ford, Lisa, Förster, Stefan, Fortea, Juan, Foskett, Nadia, Frederiksen, Kristian S., Freund-Levi, Yvonne, Frisoni, Giovanni B., Froelich, Lutz, Gabryelewicz, Tomasz, Gill, Kiran Dip, Gkatzima, Olymbia, Gómez-Tortosa, Estrella, Gordon, Mark Forrest, Grimmer, Timo, Hampel, Harald, Hausner, Lucrezia, Hellwig, Sabine, Herukka, Sanna-Kaisa, Hildebrandt, Helmut, Ishihara, Lianna, Ivanoiu, Adrian, Jagust, William J., Johannsen, Peter, Kandimalla, Ramesh, Kapaki, Elisabeth, Klimkowicz-Mrowiec, Aleksandra, Klunk, William E., Köhler, Sebastian, Koglin, Norman, Kornhuber, Johannes, Kramberger, Milica G., Van Laere, Koen, Landau, Susan M., Lee, Dong Young, de Leon, Mony, Lisetti, Viviana, Lleó, Alberto, Madsen, Karine, Maier, Wolfgang, Marcusson, Jan, Mattsson, Niklas, De Mendonça, Alexandre, Meulenbroek, Olga, Meyer, Philipp T., Mintun, Mark A., Mok, Vincent, Molinuevo, José Luis, Møllergård, Hanne M., Morris, John C., Mroczko, Barbara, Van der Mussele, Stefan, Na, Duk L., Newberg, Andrew, Nordberg, Agneta, Nordlund, Arto, Novak, Gerald P., Paraskevas, George P., Parnetti, Lucilla, Perera, Gayan, Peters, Oliver, Popp, Julius, Prabhakar, Sudesh, Rabinovici, Gil D., Ramakers, Inez H. G. B., Rami, Lorena, Resende de Oliveira, Catarina, Rinne, Juha O., Rodrigue, Karen M., Rodríguez-Rodríguez, Eloy, and Repositório da Universidade de Lisboa

Abstract

Copyright © 2015 American Medical Association. All rights reserved., Importance: Cerebral amyloid-β aggregation is an early pathological event in Alzheimer disease (AD), starting decades before dementia onset. Estimates of the prevalence of amyloid pathology in persons without dementia are needed to understand the development of AD and to design prevention studies. Objective: To use individual participant data meta-analysis to estimate the prevalence of amyloid pathology as measured with biomarkers in participants with normal cognition, subjective cognitive impairment (SCI), or mild cognitive impairment (MCI). Data sources: Relevant biomarker studies identified by searching studies published before April 2015 using the MEDLINE and Web of Science databases and through personal communication with investigators. Study selection: Studies were included if they provided individual participant data for participants without dementia and used an a priori defined cutoff for amyloid positivity. Data extraction and synthesis: Individual records were provided for 2914 participants with normal cognition, 697 with SCI, and 3972 with MCI aged 18 to 100 years from 55 studies. Main outcomes and measures: Prevalence of amyloid pathology on positron emission tomography or in cerebrospinal fluid according to AD risk factors (age, apolipoprotein E [APOE] genotype, sex, and education) estimated by generalized estimating equations. Results: The prevalence of amyloid pathology increased from age 50 to 90 years from 10% (95% CI, 8%-13%) to 44% (95% CI, 37%-51%) among participants with normal cognition; from 12% (95% CI, 8%-18%) to 43% (95% CI, 32%-55%) among patients with SCI; and from 27% (95% CI, 23%-32%) to 71% (95% CI, 66%-76%) among patients with MCI. APOE-ε4 carriers had 2 to 3 times higher prevalence estimates than noncarriers. The age at which 15% of the participants with normal cognition were amyloid positive was approximately 40 years for APOE ε4ε4 carriers, 50 years for ε2ε4 carriers, 55 years for ε3ε4 carriers, 65 years for ε3ε3 carriers, and 95 years for ε2ε3 carriers. Amyloid positivity was more common in highly educated participants but not associated with sex or biomarker modality. Conclusions and relevance: Among persons without dementia, the prevalence of cerebral amyloid pathology as determined by positron emission tomography or cerebrospinal fluid findings was associated with age, APOE genotype, and presence of cognitive impairment. These findings suggest a 20- to 30-year interval between first development of amyloid positivity and onset of dementia., The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under EMIF grant agreement No. 115372, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in-kind contribution. BIOMARKAPD is an EU Joint Programme–Neurodegenerative Disease Research (JPND) project. The project is supported through national funding organizations under the aegis of JPND (http://www.jpnd.eu). In the Netherlands, this is ZonMw. The DESCRIPA study was funded by the European Commission within the 5th framework program (QLRT-2001-2455). The EDAR study was funded by the European Commission as part of the 6th framework programme (contract No. 37670). This research was performed within the framework of the Center for Translational Molecular Medicine (CTTM) (http://www.ctmm.nl), project LeARN (grant 02N-101). The AIBL study was funded in part by the study partners (Australian Commonwealth Scientific Industrial and Research Organization [CSIRO], Edith Cowan University [ECU], Mental Health Research Institute [MHRI], Alzheimer’s Australia [AA], National Ageing Research Institute [NARI], Austin Health, CogState, Hollywood Private Hospital, Sir Charles Gardner Hospital). The study also received support from the National Health and Medical Research Council (NHMRC) and the Dementia Collaborative Research Centres program (DCRC2), as well as ongoing funding from the Science and Industry Endowment Fund (SIEF). Data collection and sharing for this project was funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (National Institutes of Health grant U01 AG024904) and the US Department of Defense ADNI (W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging and the National Institute of Biomedical Imaging and Bioengineering and through generous contributions from the following: Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; BioClinica; Biogen Idec; Bristol-Myers Squibb Company; Eisai; Elan Pharmaceuticals; Eli Lilly; F. Hoffmann-La Roche and its affiliated company Genentech; GE Healthcare; Innogenetics; IXICO; Janssen Alzheimer Immunotherapy Research & Development; Johnson & Johnson Pharmaceutical Research & Development; Medpace; Merck; Meso Scale Diagnostics; NeuroRx Research; Novartis Pharmaceuticals; Pfizer; Piramal Imaging; Servier; Synarc; and Takeda Pharmaceutical. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (http://www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. The Dementia Competence Network (DCN) has been supported by a grant from the German Federal Ministry of Education and Research (BMBF): Kompetenznetz Demenzen (01GI0420). Additional funding related to the randomized clinical trials came from Janssen-Cilag and Merz Pharmaceuticals. The latter funds were exclusively used for personnel, pharmaceuticals, blistering and shipment of medication, and monitoring and as capitation fees for recruiting centers. Funding source for the Chandigarh study is the Indian Council of Medical Research (ICMR), India. Funding for the St Louis contribution was provided by the National Institute on Aging (P50 AG005681, P01 AG003991, and P01 AG026276); Fred Simmons and Olga Mohan, and the Charles and Joanne Knight Alzheimer’s Research Initiative of the Washington University Knight Alzheimer’s Disease Research Center. The Tours study received financial support of the French Ministry of Health grant PHRC-N 2008 1004 and the EC-FP6-project DiMI, LSHB-CT-2005-512146. The Caen study was funded by Agence Nationale de la Recherche, Programme Hospitalier de Recherche Clinique, Région Basse Normandie, and Institut National de la Santé et de la Recherche Médicale (Inserm). The research leading to the Munich contribution to the Mattsson multicenter study has received funding from the program “Investissements d’avenir” (ANR-10-IAIHU-06). The study from Pittsburgh was supported by National Institutes of Health grants (P50 AG005133, R37 AG025516, P01 AG025204). The New York contributions to the Mattsson multicenter study were in part supported by P30 AG008051, R01 AG13616, R01 AG022374, and R01 AG12101. Data from Brescia in this article were collected by Translational Outpatient Memory Clinic (TOMC) working group at IRCCS Fatebenefratelli in Brescia, Italy. Contributors to the TOMC are G. Amicucci, S. Archetti, L. Benussi, G. Binetti, L. Bocchio-Chiavetto, C. Bonvicini, E. Canu, F. Caobelli, E. Cavedo, E. Chittò, M. Cotelli, M. Gennarelli, S. Galluzzi, C. Geroldi, R. Ghidoni, R. Giubbini, U. P. Guerra, G. Kuffenschin, G. Lussignoli, D. Moretti, B. Paghera, M. Parapini, C. Porteri, M. Romano, S. Rosini, I. Villa, R. Zanardini, and O. Zanetti. The JPND Project is supported in Italy by the Italian Ministry of Health. The assembling of the TU Munich data set was supported in part by the German research foundation (Deutsche Forschungsgemeinschaft) (HE 4560/1-2, DR 445/3-1 and DR 445/4-1 to A.D.), and by a KKF grant for clinical research of the Technische Universität München (to A.D. and T.G.). The Florbetaben phase 2 study from which data were derived for this multicenter evaluation was sponsored by Bayer Healthcare/Piramal Imaging (Berlin, Germany). This work was supported by the University of Antwerp Research Fund; the Alzheimer Research Foundation (SAO-FRA); the Research Foundation Flanders (FWO); the Agency for Innovation by Science and Technology (IWT); the Belgian Science Policy Office Interuniversity Attraction Poles (IAP) program; and the Flemish Government–initiated Methusalem excellence grant.

Published
2015

228. Major depressive disorder, personality disorders and coping strategies are independent risk factors for lower quality of life in non-metastatic breast cancer patients

Author

Brunault, Paul, Champagne, Anne-Laure, Huguet, Grégoire, Suzanne, Isabelle, Senon, Jean-Louis, Body, Gilles, Rusch, Emmanuel, Magnin, Guillaume, Voyer, Mélanie, Réveillère, Christian, Camus, Vincent, CHRU de Tours, Équipe de Liaison et de Soins en Addictologie, Tours, France, Clinique Psychiatrique Universitaire [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Psychologie des âges de la vie et adaptation (PAVeA), Université de Tours (UT), Unité de recherche clinique intersectorielle du Centre Hospitalier Henri Laborit, Centre Hospitalier Henri Laborit (CHL), CHU Trousseau [Tours], Centre hospitalier universitaire de Poitiers (CHU Poitiers), Imagerie et cerveau (iBrain - Inserm U1253 - UNIV Tours ), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Tours (UT), CHRU Tours, Psychologie des âges de la vie ( PAVeA ), Université de Tours, Unité de recherche clinique intersectorielle en psychiatrie du Centre Hospitalier Henri Laborit, CHU de Poitiers, Imagerie et cerveau, Université de Tours-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM), and Brunault, Paul

Subjects
[SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, [ SDV.MHEP.PSM ] Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, [SDV.MHEP.PSM] Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, [SDV.NEU.PC] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, [SHS.PSY]Humanities and Social Sciences/Psychology, [SDV.CAN]Life Sciences [q-bio]/Cancer, humanities, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, [SHS.PSY] Humanities and Social Sciences/Psychology, [ SDV.NEU.PC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, coping, [ SHS.PSY ] Humanities and Social Sciences/Psychology, [SDV.CAN] Life Sciences [q-bio]/Cancer, quality of life, [SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, MESH : cancer, oncology, quality of life, coping, depression, oncology, depression, cancer, MESH: cancer, oncology, quality of life, coping, depression
Abstract

International audience; Objective: To identify risk factors for lower quality of life (QOL) in non-metastatic breast cancer patients.Methods: Our study included 120 patients from the University Hospital Centers of Tours and Poitiers. This cross-sectional study was conducted 7 months after patients’ breast cancer diagnosis and assessed QOL (Quality of Life Questionnaire-Core 30 = QLQ-C30), socio-demographic characteristics, coping strategies (Brief-Cope), physiological and biological variables (e.g., initial tumor severity, types of treatment received), the existence of major depressive disorder (Mini International Neuropsychiatric Interview) and pain severity (QDSA). We assessed personality disorders 3 months after diagnosis (VKP questionnaire). We used multiple linear regression models to determine which factors were associated with physical, emotional and global QOL. Results: Lower physical QOL was associated with major depressive disorder, younger age, a more severe initial tumor stage and the use of the behavioral disengagement coping. Lower emotional QOL was associated with major depressive disorder, the existence of a personality disorder, a more severe pain level, higher use of self-blame and lower use of acceptance coping strategies. Lower global QOL was associated with major depressive disorder, the existence of a personality disorder, a more severe pain level, higher use of self-blame and lower use of positive reframing coping strategies and an absence of hormone therapy.Conclusions: Lower QOL scores were more strongly associated to variables related to the individual’s premorbid psychological characteristics and the manner in which this individual copes with the cancer (e.g., depression, personality and coping) than to cancer-related variables (e.g., treatment types, cancer severity).

Published
2015
Full Text
View/download PDF

229. EBV+diffuse large B-cell lymphoma associated with chronic inflammation expands the spectrum of breast implant–related lymphomas

Author

Mescam, Lénaïg, Camus, Vincent, Schiano, Jean-Marc, Adélaïde, José, Picquenot, Jean-Michel, Guille, Arnaud, Bannier, Marie, Ruminy, Philippe, Viailly, Pierre-Julien, Jardin, Fabrice, Bouabdallah, Reda, Brenot-Rossi, Isabelle, Bohers, Elodie, Robe, Cyrielle, Laurent, Camille, Birnbaum, Daniel, Wotherspoon, Andrew, Gaulard, Philippe, and Xerri, Luc

Published
2020
Full Text
View/download PDF

230. Adaptive simulation-based framework for error characterization of inexact circuits.

Author

Bonnot, Justine, Camus, Vincent, Desnos, Karol, and Menard, Daniel

Subjects
*EXTREME value theory, *ERROR rates, *APPROXIMATION error, *ERROR probability, *INFERENTIAL statistics, *QUALITY of service, *ERRORS
Abstract

To design faster and more energy-efficient systems, numerous inexact arithmetic operators have been proposed, generally obtained by modifying the logic structure of conventional circuits. However, as the quality of service of an application has to be ensured, these operators need to be precisely characterized to be usable in commercial or real-life applications. The characterization of the error induced by inexact operators is commonly achieved with exhaustive or stochastic bit-accurate gate-level simulations. However, for high bit-widths, the time and memory required for such simulations become prohibitive. To overcome these limitations, a new characterization framework for inexact operators is proposed. The proposed framework characterizes the error induced by inexact operators in terms of mean error distance, error rate and maximum error distance, allowing to completely define the error probability mass function. By exploiting statistical properties of the approximation error, the number of simulations needed for precise characterization is minimized. From user-defined confidence requirements, the proposed method computes the minimal number of simulations to obtain the desired accuracy on the characterization for the error rate and mean error distance. The maximum error distance value is then extracted from the simulated samples using the extreme value theory. For 32-bit adders, the proposed method reduces the number of simulations needed up to a few tens of thousands points. • A framework to characterize the error of inexact circuits is proposed. • The asked estimation quality allows trading-off the number of simulations. • The method is based on inferential statistics and extreme value theory. • The error rate, mean and maximum error distance are estimated. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

231. Somatic mutations of cell-free circulating DNA detected by targeted next-generation sequencing and digital droplet PCR in classical Hodgkin lymphoma.

Author

Bessi, Lucile, Viailly, Pierre-Julien, Bohers, Elodie, Ruminy, Philippe, Maingonnat, Catherine, Bertrand, Philippe, Vasseur, NasrinSarafan, Beaussire, Ludivine, Etancelin, Pascaline, Cornic, Marie, Tilly, Hervé, Stamatoullas, Aspasia, Jardin, Fabrice, Picquenot, Jean-Michel, and Camus, Vincent

Subjects
HODGKIN'S disease, SOMATIC mutation, DIFFUSE large B-cell lymphomas, CIRCULATING tumor DNA, DNA
Abstract

The article focuses on the classical Hodgkin lymphoma (cHL) account with targeted next-generation sequencing and digital droplet polymerase chain reaction (PCR) assay. It discusses the content of Hodgkin and Reed-Sternberg (HRS) cells, the extraction of CfDNA from frozen lymph node samples, and bioinformatic analysis.

Published
2019
Full Text
View/download PDF

232. Identification of primary mediastinal B-cell lymphomas with higher clonal dominance and poorer outcome using 5′RACE

Author

Camus, Vincent, Viennot, Mathieu, Viailly, Pierre-Julien, Drieux, Fanny, Veresezan, Elena-Liana, Bobée, Victor, Rainville, Vinciane, Bohers, Elodie, Sesques, Pierre, Haioun, Corinne, Durot, Eric, Bayaram, Michael, Rossi, Cédric, Martin, Laurent, Penther, Dominique, Kaltenbach, Sophie, Bruneau, Julie, Paillassa, Jérôme, Tournilhac, Olivier, Gower, Nicolas, Willaume, Alexandre, Antier, Chloé, Renaud, Loïc, Lévêque, Emilie, Decazes, Pierre, Becker, Stéphanie, Tonnelet, David, Gaulard, Philippe, Tilly, Hervé, Molina, Thierry Jo, Traverse-Glehen, Alexandra, Donzel, Marie, Ruminy, Philippe, and Jardin, Fabrice

Abstract

•BCR repertoire analysis revealed frequent AID-initiated somatic hypermutation, isotype switching, and immunoglobulin gene fusion transcripts.•The 5′RACE assay identified patients with strongly dominant clonotypes, a greater degree of tumoral infiltration, and poorer outcomes.

Published
2024
Full Text
View/download PDF

233. Efficacy of CAR T-Cell Therapy is Not Impaired by Previous Bispecific Antibody Treatment in Large B-Cell Lymphoma

Author

Crochet, Gilles, Iacoboni, Gloria, Couturier, Audrey, Bachy, Emmanuel, Iraola-Truchuelo, Josu, Gastinne, Thomas, Cartron, Guillaume, Fradon, Tom, Lesne, Bastien, Kwon, Mi, Gounot, Romain, Martinez-Cibrian, Nuria, Castilla-Llorente, Cristina, Abrisqueta, Pau, Guerreiro, Manuel, Sarkozy, Clementine, Aspa-Cilleruelo, Jose, Camus, Vincent, Guidez, Stéphanie, Chauchet, Adrien, Deconinck, Eric, Bouabdallah, Krimo, Bosch, Francesc, Barba, Pere, Morschhauser, Franck, and Houot, Roch

Abstract

In this retrospective study, CAR T-cells remained effective in relapsed/refractory LBCL patients after prior exposure to bispecific antibodies (BsAbs) targeting different antigens. These results are relevant to clinical practice, particularly given the increasing use of BsAbs in earlier treatment lines.

Published
2024
Full Text
View/download PDF

234. Cerebral Metabolic Signature of Chronic Benzodiazepine Use in Nondemented Older Adults: An FDG-PET Study in the MEMENTO Cohort

Author

Gallet, Quentin, Bouteloup, Vincent, Locatelli, Maxime, Habert, Marie-Odile, Chupin, Marie, Campion, Jacques-Yves, Michels, Pierre-Emmanuel, Delrieu, Julien, Lebouvier, Thibaud, Balageas, Anna-Chloé, Surget, Alexandre, Belzung, Catherine, Arlicot, Nicolas, Ribeiro, Maria-Joao Santiago, Gissot, Valérie, El-Hage, Wissam, Camus, Vincent, Gohier, Bénédicte, and Desmidt, Thomas

Abstract

•What is the primary question addressed by this study?This study explores the association between chronic BZD use and FDG-PET brain metabolism in the MEMENTO clinical cohort of nondemented older adults with isolated memory complaint or mild cognitive impairment.•What is the main finding of this study?The authors found that brain metabolism was significantly greater in chronic BZD users compared to non-users in the whole brain and in the right amygdala, independent of potential confounders.•What is the meaning of the finding?Chronic BZD use may induce a compensatory mechanism which consists in a global metabolism upregulation in the brain, with a specific focus on the right amygdala as a specific target for BZD action.

Published
2024
Full Text
View/download PDF

240. Dépression résistante : les stratégies de changement et d’association de médicaments antidépresseurs

Author

Charpeaud, Thomas, primary, Moliere, Fanny, additional, Bubrovszky, Maxime, additional, Haesebaert, Frédéric, additional, Allaïli, Najib, additional, Bation, Rémy, additional, Nieto, Isabel, additional, Richieri, Raphaëlle, additional, Saba, Ghassen, additional, Bellivier, Frank, additional, Bennabi, Djamila, additional, Holtzmann, Jérôme, additional, Camus, Vincent, additional, Courtet, Philippe, additional, Courvoisier, Pierre, additional, d’Amato, Thierry, additional, Doumy, Olivier, additional, Garnier, Marion, additional, Bougerol, Thierry, additional, Lançon, Christophe, additional, Haffen, Emmanuel, additional, Leboyer, Marion, additional, Llorca, Pierre-Michel, additional, Vaiva, Guillaume, additional, El-Hage, Wissam, additional, and Aouizerate, Bruno, additional

Published
2016
Full Text
View/download PDF

241. Dépression résistante : les stratégies de potentialisation

Author

Doumy, Olivier, primary, Bennabi, Djamila, additional, El-Hage, Wissam, additional, Allaïli, Najib, additional, Bation, Rémy, additional, Bellivier, Frank, additional, Holtzmann, Jérôme, additional, Bubrovszky, Maxime, additional, Camus, Vincent, additional, Charpeaud, Thomas, additional, Courvoisier, Pierre, additional, d’Amato, Thierry, additional, Garnier, Marion, additional, Haesebaert, Frédéric, additional, Bougerol, Thierry, additional, Lançon, Christophe, additional, Moliere, Fanny, additional, Nieto, Isabel, additional, Richieri, Raphaëlle, additional, Saba, Ghassen, additional, Courtet, Philippe, additional, Vaiva, Guillaume, additional, Leboyer, Marion, additional, Llorca, Pierre-Michel, additional, Aouizerate, Bruno, additional, and Haffen, Emmanuel, additional

Published
2016
Full Text
View/download PDF

242. Quelle définition pour la dépression résistante ?

Author

Holtzmann, Jérôme, primary, Richieri, Raphaëlle, additional, Saba, Ghassen, additional, Allaïli, Najib, additional, Bation, Rémy, additional, Moliere, Fanny, additional, Nieto, Isabel, additional, Bellivier, Frank, additional, Bennabi, Djamila, additional, Bubrovszky, Maxime, additional, Camus, Vincent, additional, Charpeaud, Thomas, additional, Courvoisier, Pierre, additional, Haesebaert, Frédéric, additional, Doumy, Olivier, additional, Courtet, Philippe, additional, El-Hage, Wissam, additional, Garnier, Marion, additional, d’Amato, Thierry, additional, Lançon, Christophe, additional, Leboyer, Marion, additional, Llorca, Pierre-Michel, additional, Vaiva, Guillaume, additional, Bougerol, Thierry, additional, Aouizerate, Bruno, additional, and Haffen, Emmanuel, additional

Published
2016
Full Text
View/download PDF

243. Digital PCR for quantification of recurrent and potentially actionable somatic mutations in circulating free DNA from patients with diffuse large B-cell lymphoma

Author

Camus, Vincent, primary, Sarafan-Vasseur, Nasrin, additional, Bohers, Elodie, additional, Dubois, Sydney, additional, Mareschal, Sylvain, additional, Bertrand, Philippe, additional, Viailly, Pierre-Julien, additional, Ruminy, Philippe, additional, Maingonnat, Catherine, additional, Lemasle, Emilie, additional, Stamatoullas, Aspasia, additional, Picquenot, Jean-Michel, additional, Cornic, Marie, additional, Beaussire, Ludivine, additional, Bastard, Christian, additional, Frebourg, Thierry, additional, Tilly, Hervé, additional, and Jardin, Fabrice, additional

Published
2016
Full Text
View/download PDF

244. Personality disorders, but not cancer severity or treatment type, are risk factors for later generalised anxiety disorder and major depressive disorder in non metastatic breast cancer patients

Author

Champagne, Anne-Laure, primary, Brunault, Paul, additional, Huguet, Grégoire, additional, Suzanne, Isabelle, additional, Senon, Jean-Louis, additional, Body, Gilles, additional, Rusch, Emmanuel, additional, Magnin, Guillaume, additional, Voyer, Mélanie, additional, Réveillère, Christian, additional, and Camus, Vincent, additional

Published
2016
Full Text
View/download PDF

245. Recurrent Mutations of the Exportin 1 Gene (XPO1) in Primary Mediastinal B-Cell Lymphoma: A Lysa Study

Author

Jardin, Fabrice, primary, Pujals, Anais, additional, Pelletier, Laura, additional, Bohers, Elodie, additional, Camus, Vincent, additional, Mareschal, Sylvain, additional, Dubois, Sydney, additional, Ochman, Marlène, additional, Lemonnier, Francois, additional, Viailly, Pierre-Julien, additional, Bertrand, Philippe, additional, Maingonnat, Catherine, additional, Traverse-Glehen, Alexandra, additional, Gaulard, Philippe, additional, Damotte, Diane, additional, Delarue, Richard, additional, Haioun, Corinne, additional, Landesman, Yosef, additional, Senapedis, William, additional, Argueta, Christian, additional, Salles, Gilles Andre, additional, Jais, Jean-Philippe, additional, Figeac, Martin, additional, Copie-Bergman, Christiane, additional, Molina, Thierry, additional, Picquenot, Jean-Michel, additional, Cornic, Marie, additional, Fest, Thierry, additional, Milpied, Noel, additional, Lemasle, Emilie, additional, Stamatoullas, Aspasia, additional, Moeller, Peter, additional, Dyer, Martin JS, additional, Sundstrom, Christer, additional, Bastard, Christian, additional, Tilly, Hervé, additional, and Leroy, Karen, additional

Published
2015
Full Text
View/download PDF

246. Somatic Mutations Detected in Plasma Cell-Free DNA By Targeted Sequencing: Assessment of Liquid Biopsy in Primary Central Nervous System Lymphoma

Author

Fontanilles, Maxime, primary, Marguet, Florent, additional, Bohers, Élodie, additional, Viailly, Pierre-Julien, additional, Bertrand, Philippe, additional, Dubois, Sydney, additional, Mareschal, Sylvain, additional, Camus, Vincent, additional, Veresezan, Elena-Liana, additional, Ruminy, Philippe, additional, Tilly, Hervé, additional, Laquerriere, Annie, additional, Picquenot, Jean-Michel, additional, and Jardin, Fabrice, additional

Published
2015
Full Text
View/download PDF

247. Comorbidity between personality disorders and depressive symptomatology in women: A cross-sectional study of three different transitional life stages

Author

Enfoux, Aurore, Courtois, Robert, Duijsens, Inge, Réveillère, Christian, Senon, Jean Louis, Magnin, Guillaume, Voyer, Melanie, Montmasson, Helene, Camus, Vincent, El-Hage, Wissam, Psychologie des âges de la vie et adaptation (PAVeA), Université de Tours, Clinique Psychiatrique Universitaire [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Service de gynécologie et obstétrique [Poitiers], Centre hospitalier universitaire de Poitiers (CHU Poitiers), Imagerie et cerveau (iBrain - Inserm U1253 - UNIV Tours ), Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Tours (UT), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Tours (UT)

Subjects
[SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, [SHS.PSY]Humanities and Social Sciences/Psychology, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2013
Full Text
View/download PDF

248. Sleep and mood changes in advanced age after blue-blocking (yellow) intra ocular lens (IOLs) implantation during cataract surgical treatment: a randomized controlled trial.

Author

Desmidt, Thomas, Bellicaud, David, Limousin, Nadège, Zambrowski, Olivia, Camus, Vincent, Autret-Leca, Elisabeth, Pisella, Pierre-Jean, Hommet, Caroline, Souied, Eric H, Tavernier, Elsa, Le Gouge, Amélie, and Cochener, Béatrice

Subjects
AFFECT (Psychology), AGING, CATARACT surgery, HOSPITAL wards, INTRAOCULAR lenses, POSTOPERATIVE period, PSYCHOLOGICAL tests, SLEEP, SURGICAL therapeutics, TIME, RANDOMIZED controlled trials
Abstract

Objectives: Both advanced age and depression are characterized by changes in sleep patterns. Light exposure is one of the main synchronizers of circadian cycles and influences sleep by inhibiting melatonin secretion, which is mostly sensitive to light of low wavelengths (blue). Blue-blocking (yellow) intraocular lenses (IOLs) have supplanted the usual UV-blocking (clear) IOLs during cataract surgery to prevent age-related macular degeneration, however, the impact of yellow IOLs on sleep and mood is unclear. The purpose of this study was to compare the effects of yellow and clear IOLs on sleep and mood in aged patients undergoing bilateral cataract surgery. Methods: A randomized controlled superiority study was conducted within three ophthalmic surgical wards in France. A total of 204 subjects (mean age 76.2 ± 7.5 years) were randomized into yellow or clear IOLs groups. Patients completed a sleep diary, the pictorial sleepiness scale and the Beck Depression Inventory (BDI) one week before and eight weeks after the last surgical procedure. Results: According to an Intent To Treat (ITT) analysis, no significant difference was found between yellow and clear IOLs groups regarding sleep time, sleep latency, total sleep duration, quality of sleep and BDI scores. The rate of patients whose BDI score increased at the cutoff score of ≥5 after surgery was significantly higher in the yellow IOL group (n = 11, 13.1%) compared with the clear IOL group (n = 4; 4.7%); p = 0.02. Conclusions: Using yellow IOLs for cataract surgery doesn't significantly impact sleep but may induce mood changes in aging. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results